Back
65· Active
Health & Science2d 11h ago
The FDA has granted orphan drug designation to NP-402, a first-in-class synthetic peptide designed to disrupt protein aggregate formation in early-onset Alzheimer's patients.
Silver Spring, MD / San Diego, CA
Who
U.S. Food and Drug Administration (FDA) / Neuromics Pharma
What
The FDA has granted orphan drug designation to NP-402, a first-in-class synthetic peptide designed to disrupt protein aggregate formation in early-onset Alzheimer's patients.
When
Sat, 06 Jun 2026 22:10:05 GMT · 2d 11h ago
Where
Silver Spring, MD / San Diego, CA · 39.0350°N, 76.9950°W
Why
This move follows positive Phase 1b safety data suggesting the drug can cross the blood-brain barrier effectively for targeted delivery.
The Frontline Impact
How this affects you
If further trials succeed, this could provide a specialized treatment path for rare, genetic forms of dementia with potentially fewer side effects than current monoclonal antibodies.
Story chain
1 event in this threadNo related history yet — this is the origin event.
Verified Sources & Citations
Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.